Future Ventures is proud to have led the Series A financing of Osmind, announced today. Congrats to Lucia, Jimmy and their stellar team! The company aims to usher in a new era of neuropsychiatry by leveraging technology and data to enable precision mental healthcare, much like we saw in oncology over the past decade. Think of it as the operating system for a sector undergoing rapid change.
And the need is great, and rapidly growing. Osmind is accelerating a renaissance in one of the most broken areas of healthcare. During the COVID-19 pandemic, the prevalence of depression tripled. The World Health Organization predicts that—without significant changes—mental illness will cost the world economy $16 trillion by 2030, making it the largest disease burden globally. A new generation of psychedelic therapies in FDA trials are showing unprecedented cure rates. Change is coming, and Osmind can help humanity learn how to heal.
“Osmind’s modern EHR is the first and only software that solves specific challenges faced by innovative mental health practices. It allows clinicians to track measurement-based outcomes for intensive treatment modalities and deliver more tailored care, automates compliance processes for the U.S. FDA and insurance companies, and streamlines patient and practice management. The software also aggregates de-identified real-world data to accelerate research and development of new mental health treatments and diagnostics such as psychedelic medicines, neuromodulation, digital therapeutics, digital phenotyping, and neuroimaging.” — Announcement today
* Company Site
• Forbes
Leave a Reply